<DOC>
	<DOCNO>NCT02591771</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety i.v . adrenaline infusion early fast haemodynamic stabilizer , associate tight tissue perfusion monitoring , context stepwise progression treatment cardiogenic shock , include ventricular mechanical support .</brief_summary>
	<brief_title>Study Multistep Pharmacological Invasive Management Cardiogenic Shock</brief_title>
	<detailed_description>Cardiogenic shock characterize decrease cardiac output increase ventricular pressure , subsequent symptom sign systemic hypoperfusion . In spite multiple pharmacological chance in-hospital mortality rate still high ( around 60 % patient ) nowadays therapeutic `` reference standard '' associate improve survival short midterm . Adrenaline mainstay resuscitation therapy cardiopulmonary arrest , however , clear whether inotrope actually facilitate improvement patient affect cardiogenic shock . In small local evidence-based experience , contrary current opinion , show adrenaline may still role treatment patient low output state . This phase II study test hypothesis adrenaline infusion , integrate multistep approach increase intensity , valid support limit side effect .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Shock , Cardiogenic</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Age â‰¥ 18 , male female Eligible patient fit least two follow criteria/items : Systolic Blood Pressure &lt; 100 mmHg Medium Arterial Pressure &lt; 60 mmHg , fluid challenge ( least 1000 ml crystalloid solution 500 ml colloidal solution right atrial pressure &gt; 4 mmHg ) Central Venous Pressure &gt; 12 mmHg Wedge Pressure &gt; 14 mmHg . Mixed venous oxygen saturation &lt; 60 % Arterial lactate &gt; 2 Oliguria &lt; 0.5 ml/Kg/h Pregnant , lactate subject plan pregnancy course trial . Participants involve clinical trial . Ongoing major arrhythmia : Ventricular Tachycardia Ventricular Fibrillation Atrial Fibrillation , ventricular rate &gt; 160 bpm Inability sign inform consent Low output state due hypovolemia ( right atrial pressure &lt; 4 mmHg ) Septic shock Severe Aortic mitral stenosis Obstructive hypertrophic cardiomyopathy constrictive pericarditis severe congenital cardiomyopathy Comorbidities ominous prognosis ( life expectancy &lt; 1 year ) Overt infection , hepatic , renal pulmonary dysfunction , alter neurological status without clear prognosis acute cardiac arrest follow cardiogenic shock Any significant disease disorder , opinion Investigator , may either put participant risk participation trial , may influence result trial , participant 's ability participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adrenaline</keyword>
	<keyword>Extra Corporeal Life Support</keyword>
	<keyword>Inotropes</keyword>
</DOC>